GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent

GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med

GSK drug Nucala has expanded its FDA-approved uses to include maintenance treatment of chronic obstructive pulmonary disease that’s driven by eosinophils, a type of immune cell. The antibody drug will compete against the blockbuster Sanofi product Dupixent, which expanded its FDA approval to COPD last year. The post GSK Inflammation Drug Lands New FDA Nod in COPD, Stiffening Competition With Sanofi Med appeared first on MedCity News.

US Approves GSK’s Lung Disease Drug, Fueling Rivalry With Sanofi

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

GSK’s Nucala wins U.S. nod as first IL-5 biologic for COPD

The FDA on May 22 cleared GSK’s interleukin-5 antibody Nucala (mepolizumab) as an add-on to inhaled triple therapy for adults whose chronic obstructive pulmonary disease keeps flaring despite treatment and whose blood-eosinophil count starts at 150 cells/µL. The approval is on the basis of the MATINEE and METREX phase 3 trials. The MATINEE study, which… The post GSK’s Nucala wins U.S. nod as first IL-5 biologic for COPD appeared first on Drug Di…

GSK’s Nucala wins COPD approval, stoking rivalry with Dupixent

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary disease, setting up a showdown with Sanofi and Regeneron’s Dupixent. The label expansion will make Nucala ...

The US Food and Drug Administration (FDA) has approved the use of an asthma drug from British company GSK to treat some cases of the chronic lung disease, commonly known as "smoker's lung", Reuters reported.